The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.
The semaphorins and their receptors, the neuropilins and the plexins, are constituents of a complex regulatory system that controls axonal guidance. Moreover, many types of tumor cells express various members of semaphorins and receptors, but the biological activities within tumor mass and the signal transduction mechanism(s) they use are largely unknown. Here, we show that in asbestos-related malignant pleural mesothelioma (MPM), Semaphorin-6D (Sema6D) and its receptor plexin-A1 are frequently expressed and trigger a prosurvival program that promotes anchorage-independent growth of MPM cells. Interestingly, the same response is also controlled by the tyrosine kinase receptors of vascular endothelial growth factor (VEGF) through a nuclear factor-kappaB (NF-kappaB)-dependent pathway. We found that in MPM cells, plexin-A1 and VEGF-receptor 2 (VEGF-R2) are associated in a complex. Moreover, the presence of Sema6D promotes the tyrosine phosphorylation of VEGF-R2 in a plexin-A1-dependent manner. This is necessary for basal and Sema6D-induced NF-kappaB transcriptional activity, and NF-kappaB mediates tumor cell survival. Expression of Sema6D and plexin-A1 is induced by asbestos fibers and overexpression of plexin-A1 in nonmalignant mesothelial cells inhibits cell death after asbestos exposure. This work identifies a new biological function of semaphorins in cancer cells and suggests the involvement of an undescribed survival pathway during MPM tumorigenesis.
Catalano
Alfonso
A
Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy. a.catalano@univpm.it
Lazzarini
Raffaella
R
Di Nuzzo
Silvia
S
Orciari
Silvia
S
Procopio
Antonio
A
D017209:Apoptosis; D002448:Cell Adhesion; D002455:Cell Division; D002470:Cell Survival; D003114:Colony-Forming Units Assay; D017930:Genes, Reporter; D006801:Humans; D015151:Immunoblotting; D008654:Mesothelioma / Q000235:genetics / Q000473:pathology*; D016328:NF-kappa B / Q000235:genetics* / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000235:genetics*; D010641:Phenotype; D010957:Plasmids; D010997:Pleural Neoplasms / Q000235:genetics / Q000473:pathology*; D012334:RNA, Neoplasm / Q000235:genetics; D011956:Receptors, Cell Surface / Q000235:genetics*; D015398:Signal Transduction; D014162:Transfection; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000502:physiology; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics*
D016328:NF-kappa B; D009419:Nerve Tissue Proteins; C492116:PLXNA1 protein, human; D012334:RNA, Neoplasm; D011956:Receptors, Cell Surface; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2